Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Human adipose-derived mesenchymal stem cells-derived exosomes encapsulated in pluronic F127 hydrogel promote wound healing and regeneration.

Zhou Y., Zhang XL., Lu ST., Zhang NY., Zhang HJ., Zhang J.

Prospective Study on Chronic Wound, published in Stem Cell Res Ther (2022) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Stem Cell Res Ther (2022)
Country
England
Reported sample size
—
Source database
PubMed
PMID
35941707
PMCID
PMC9358082
DOI
10.1186/s13287-022-02980-3
Citations
148

Abstract (original English)

Abstract Background : Large area skin trauma has always been a great challenge for both patients and clinicians. Exosomes originated from human adipose-derived mesenchymal stem cells (hADSCs) have been a novel promising cell-free treatment in cutaneous damage repair. Nevertheless, the low retention rate of exosomes post-transplantation in vivo remains a significant challenge in clinical applications. Herein, we purposed to explore the potential clinical application roles of hADSCs-Exos encapsulated in functional PF-127 hydrogel in wound healing. Methods : hADSCs-Exos were isolated from human hADSCs by ultracentrifugation. An injectable, biocompatible, and thermo-sensitive hydrogel Pluronic F-127 hydrogel was employed to encapsulate allogeneic hADSCs-Exos, and this complex was topically applied to a full-thickness cutaneous wound in mice. On different days post-transplantation, the mice were sacrificed, and the skin tissue was excised for histological and immunohistochemical analysis. Results : PF-127/hADSCs-Exos complex enhanced skin wound healing, promoted re-epithelialization, increased expression of Ki67, α-SMA, and CD31, facilitated collagen synthesis (Collagen I, Collagen III), reduced inflammation (IL-6, TNF-α, CD68, CD206), and up-regulated expression of skin barrier proteins (KRT1, AQP3). The results showed that both PF-127/hADSCs-Exos and hADSCs-Exos could improve the

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AnimalsCollagenExosomesHumansHydrogelsMesenchymal Stem CellsMicePoloxamerWound Healing

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research